Floatz logo

Nerispirdine

Optic Nerve

SanofiSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Optic Nerve cohort.

Asset / SponsorPhaseRating
Cnm-Au8
Clene Nanomedicine
Phase 2CCC

Same molecule, other indications

Nerispirdine is also rated in:

neuritisDormant
B
Indicative ·
57 / 100
View asset →
multiple sclerosisDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →